FCMI
CRNX

Foresite Capital Management IV’s Crinetics Pharmaceuticals CRNX Stock Holding History

Foresite Capital Management IV’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.61M Buy
+150,000
New +$5.58M 1.93% 6
2018
Q4 		– Sell
-49,600
Closed -$1.42M – 19
2018
Q3 		$1.42M Buy
+49,600
New +$1.47M 0.47% 19

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Foresite Capital Management IV's CRNX Position: Q2 2026 in Review

Foresite Capital Management IV opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 150,000 shares worth $5.61M. The stake represents 1.93% of the portfolio and ranks #6 among its holdings. This is a return to the name: Foresite Capital Management IV previously reported a position in CRNX as recently as Q3 2018.

Foresite Capital Management IV first reported a position in CRNX in Q3 2018 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Foresite Capital Management IV held 150,000 shares of Crinetics Pharmaceuticals worth $5.61M as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Foresite Capital Management IV position in Q2 2026.
  • Crinetics Pharmaceuticals made up 1.93% of Foresite Capital Management IV's portfolio in Q2 2026, its #6 holding.
  • Foresite Capital Management IV first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Foresite Capital Management IV's 13F filing for Q2 2026, filed 14 Aug 2026.